Dmytro Kharkov

Global Fatty Liver Day effort sees Altimmune drive progress in liver disease treatment

Global Fatty Liver Day effort sees Altimmune drive progress in liver disease treatment
Altimmune pushes liver disease innovation

Altimmune is contributing to improved outcomes for patients with metabolic dysfunction-associated steatohepatitis (MASH) and serious liver disease, marking its role during Global Fatty Liver Day.

The company underscores its commitment to advancing innovation within the liver disease community, working in tandem with partners and stakeholders to develop new solutions. Fatty liver diseases, including MASH, remain significant health challenges worldwide, spurring ongoing research and novel therapies from biotech leaders such as Altimmune.

Altimmune recently joined the Jefferies Healthcare Conference in New York, with leadership hosting a fireside chat on June 4, according to company statements. The company also participated in the Goldman Sachs Global Healthcare Conference, scheduling a June 10 fireside chat in Miami, as previously reported here. These appearances highlight Altimmune’s ongoing engagement with the biopharma investment community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.